Abstract: The present invention relates to a method for increasing embryo implantation rate in mother's uterus in mammals by administering to the uterus of a mammal an effective amount of beta-galactoside-binding lectin or derivatives thereof, as well as to a product comprising said lectin.
Type:
Grant
Filed:
December 9, 2011
Date of Patent:
May 2, 2017
Assignees:
UNIVERSIDADE DE SÃO PAULO-USP, INPRENHA BIOTECHNOLOGIA E DESENVOLVIMENTO AVANçADO LTDA-ME
Inventors:
Marcelo Dias Baruffi, Erika da Silva Carvalho Morani, Marcelo Roncoletta, Camillo del Cistia Andrade, Lilian Cataldi Rodrigues
Abstract: The present invention provides an antibody or antigen binding fragment thereof, that binds to TM4SF5, and uses thereof. The antibody of this invention inhibits the growth, metastasis and invasion of cancer cells expressing TM4SF5 by binding to a tumor-specific antigen, TM4SF5, with high affinity, and therefore can be used to diagnose, prevent or treat various cancers expressing TM4SF5.
Type:
Grant
Filed:
February 26, 2014
Date of Patent:
April 25, 2017
Assignee:
Industry Academic Cooperation Foundation, Hallym University
Abstract: Disclosed herein are anti-LGR4 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR4 without disrupting LGR4-RSPO1 binding or signaling, and may disrupt LGR4 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for antibodies that bind LGR4, for example without disrupting LGR4-RSPO binding or signaling.
Type:
Grant
Filed:
June 17, 2015
Date of Patent:
April 25, 2017
Assignee:
Bionomics, Inc.
Inventors:
Christopher L. Reyes, Kristen M. Smith, Peter Chu, Lioudmila A. Campbell, Eric Ailor
Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
Abstract: A bispecific antibody format devoid of an active Fc moiety comprising a monovalent binding site for a death receptor and at least one binding site for a cell surface antigen expressed on B-cells, for use in the treatment or prevention of B cell mediated autoimmune diseases.
Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.
Type:
Grant
Filed:
March 23, 2015
Date of Patent:
April 18, 2017
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Jonathan Braun, Lynn K. Gordon, Kaori Shimazaki Dadgostar, Madhuri Wadehra, Kathy A. Kelly, Anna M. Wu
Abstract: Four and a Half LIM domains protein 1 (FHL-1) mutations at positions 128 or 224 that are associated with X-linked muscular myopathy, methods of screening subjects to identify those susceptible to muscular myopathy including muscular dystrophy and cardiomyopathy and kits.
Type:
Grant
Filed:
August 26, 2015
Date of Patent:
April 11, 2017
Assignee:
Centre for Addiction and Mental Health
Inventors:
John Vincent, Christian Windpassinger, Stefan Quasthoff
Abstract: The present invention relates to the field of recombinant protein production in bacterial hosts. It further relates to extraction of soluble, active recombinant protein from an insoluble fraction without the use of denaturation and without the need for a refolding step. In particular, the present invention relates to a production process for obtaining high levels a soluble recombinant Type 1 interferon protein from a bacterial host.
Type:
Grant
Filed:
October 15, 2015
Date of Patent:
April 4, 2017
Assignee:
PFENEX INC.
Inventors:
Jeffrey Allen, Ping-Hua Feng, Anant Patkar, Keith L. Haney, Lawrence Chew, Lei Lei Phokham Sengchanthalangsy
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
Type:
Grant
Filed:
January 13, 2016
Date of Patent:
March 28, 2017
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Huang, Martin J. Corbett, Joseph E. Myers, Jr., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
Abstract: The present invention addresses the problem of providing a means which is effective for the induction of the differentiation of a brown adipocyte and therefore enables a brown adipocyte to be used for and applied to, for example, the prevention/treatment of obesity or metabolic syndrome. Provided is a brown adipocyte differentiation-inducing agent containing, as an active ingredient, (1) CREG1 protein or (2) an expression vector carrying CREG1 gene.
Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.
Abstract: Described are polypeptides and their use for screening and drug discovery. More specifically, the disclosure provides chimeric polypeptides comprising a membrane protein, in particular a GPCR, fused to a binding domain, wherein the binding domain is directed against and/or specifically binds to the membrane protein. In particular, the chimeric polypeptides are single proteins wherein, in an intramolecular reaction, the binding domain stabilizes the membrane protein in a conformation of interest. Also provided are nucleic acid sequences encoding such chimeric polypeptides, cells capable of expressing such chimeric polypeptides as well as cellular compositions derived thereof. Also screening methods for compounds using the chimeric polypeptides.
Type:
Grant
Filed:
January 30, 2014
Date of Patent:
March 14, 2017
Assignees:
VIB VZW, Vrije Universiteit Brussel
Inventors:
Jan Steyaert, Toon Laeremans, Els Pardon
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
Type:
Grant
Filed:
September 27, 2013
Date of Patent:
March 14, 2017
Assignees:
INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Lorraine, Cantre Hospitalier et Universitaire de Nancy (CHU), Universite Paris Diderot-Paris 7, Universite Paris Descartes
Inventors:
Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
Type:
Grant
Filed:
September 28, 2016
Date of Patent:
March 14, 2017
Assignee:
Kiniksa Pharmaceuticals, Ltd.
Inventors:
Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
Type:
Grant
Filed:
August 7, 2015
Date of Patent:
March 7, 2017
Assignee:
REGENERON PHARMACEUTICALS, INC.
Inventors:
Haruka Okamoto, Mark Sleeman, Joyce Harp
Abstract: The instant invention provides methods and compositions for the treatment, prevention and diagnosis of for example, platelet aggregation or clot formation in a subject. The invention inhibits the activity of decreases the amount of neutrophils in the subject by inhibiting the activity or production of IL-6, interferon-gamma, STAT1, or cathepsin G. The invention addresses decreasing the amount of neutrophils in an attempt to treat subjects that have or are at risk of developing a vascular occlusive disease, an ischemia or reperfusion injury, an acute or chronic inflammatory state, autoimmune disease, myelodysplastic syndrome, tissue injury from surgery or accidental trauma, acute bacterial or viral infection, has undergone a microvascular surgical reconstructive procedure, is receiving granulocyte colony stimulating factor therapy, receiving stem cell therapy, or has sickle cell anemia.
Abstract: A monoclonal secretory IgA antibody, which binds to and neutralizes human TNF?. The secretory antibody is useful in treating a variety of inflammatory conditions in humans.
Type:
Grant
Filed:
December 14, 2012
Date of Patent:
February 28, 2017
Assignee:
Synthon Biopharmaceuticals B.V.
Inventors:
Gerardus Joseph Andreas Ariaans, Frans van Dalen, Declan Thomas Nolan
Abstract: A monoclonal secretory IgA antibody, which binds to and neutralizes a human proinflammatory cytokine or which binds to and blocks a human proinflammatory cytokine receptor. The secretory IgA antibody is useful in treating a variety of inflammatory diseases in humans.
Type:
Grant
Filed:
December 14, 2012
Date of Patent:
February 21, 2017
Assignee:
Synthon Biopharmaceuticals B.V.
Inventors:
Gerardus Joseph Andreas Ariaans, Frans van Dalen, Declan Thomas Nolan
Abstract: The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
Type:
Grant
Filed:
August 20, 2013
Date of Patent:
February 21, 2017
Assignees:
Sanofi Biotechnology, Regeneron Pharmaceuticals, Inc.
Inventors:
Marius Ardeleanu, Namita A. Gandhi, Neil Graham, Stephanie C. Kirkesseli, Sudeep Kundu, Ross E. Rocklin, Allen Radin, Steven P. Weinstein, Jennifer Davidson Hamilton, Jeffrey Ming